NDC 50242-245 – Phesgo
Pertuzumab 1200 mg/15mL; Trastuzumab 600 mg/15mL; Hyaluronidase (human Recombinant) 30000 U/15mL · Injection, Solution · Subcutaneous
Product NDC50242-245
Product details
- Brand name
- Phesgo
- Generic name
- Pertuzumab, trastuzumab, and hyaluronidase-zzxf
- Labeler
- Genentech, Inc.
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761170
- Marketed since
- June 29, 2020
- Listing expires
- December 31, 2027
- Pharmacologic class
- Endoglycosidase; HER2/neu Receptor Antagonist; HER2/neu Receptor Antagonist
Active ingredients
- Pertuzumab 1200 mg/15mL
- Trastuzumab 600 mg/15mL
- Hyaluronidase (human Recombinant) 30000 U/15mL
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 50242-245-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-245-01) / 15 mL in 1 VIAL, SINGLE-DOSE | Jun 29, 2020 |
| 50242-245-86 sample | 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-245-86) / 15 mL in 1 VIAL, SINGLE-DOSE | May 3, 2021 |
Other Phesgo products
- 50242-260 Pertuzumab 600 mg/10mL; Trastuzumab 600 mg/10mL; Hyaluronidase (human… · Injection, Solution · Genentech, Inc.